All In Biotech

Drug Trial Radar · NCT02923986

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

A Phase Ib/IIa Single-arm, Open-label Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Including Chronic Phase Patients Who Have Failed Initial Tyrosine Kinase Inhibitor (TKI) Therapy, Accelerated or Blast Phase, Ph+ Acute Myeloid Leukemia (AML) or High-risk Ph+ Myelodysplastic Syndrome (MDS)

Last checked: Nov 19, 2026Latest source record: May 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Sep 1, 2017

Primary completion

May 27, 2020

Study completion May 27, 2020

Sponsor

Lead sponsor
Bio-Path Holdings, Inc.Industry
Sponsor type
Industry
First posted
Oct 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the Phase Ib study is to determine the dose-limiting toxicity (DLT) and maximal tolerated dose (MTD) of BP1001 in combination with dasatinib in patients with with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) including chronic phase patients who have failed initial tyrosine kinase inhibitor (TKI) therapy, accelerated or blast phase, Ph+ Acute Myeloid Leukemia (AML) or High-risk Ph+ Myelodysplastic Syndrome (MDS). The primary objective of the Phase IIa study is to assess the efficacy of the combination of BP1001 and dasatinib in patients with Ph+ CML, Ph+AML, or high-risk Ph+ MDS.

Conditions

  • Chronic Myelogenous Leukemia, Ph1-Positive
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Interventions

  • BP1001 (varying dose)Drug

    BP1001 (varying dose)

  • BP1001 (fixed dose)Drug

    BP1001 (fixed dose)

  • DasatinibDrug

    Dasatinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity of BP1001 using non-hematologic and hematologic parameters per NCI CTCAE criteriaTime frame: 240 days
  2. Maximum Tolerated Dose of BP1001 using non-hematologic and hematologic parameters per NCI CTCAE criteriaTime frame: 240 days
  3. Efficacy of the combination of BP1001 and Das using hematologic response by bone marrow aspirate or biopsy and complete blood countsTime frame: 240 days
  4. Efficacy of the combination of BP1001 and Das using cytogenetic response (karyotyping) by bone marrow aspirate or biopsyTime frame: 240 days
  5. Efficacy of the combination of BP1001 and Das using molecular response (PCR) by bone marrow aspirate or biopsyTime frame: 240 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.